Programmdetails

Primary results from HELIOS-B, a phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Real-World-Daten zu Effizienz und Sicherheit einer Therapie mit Tafamidis 61 mg zur Behandlung der ATTR-CM

Outpatient Heart Failure Worsening in Patients with Cardiac Transthyretin Amyloidosis: Results from the Apollo-B Trial

Protective RXFP1 Properties in Distinct Murine Heart Failure Models

The Anrep Effect in Hypertrophic Obstructive Cardiomyopathy: A New Paradigm for Clinical Intervention

Initial clinical experience with mavacamten in symptomatic oHCM patients

Clinical and echocardiographic long-term follow-up after transcoronary ablation of septal hypertrophy – a retrospective register analysis

Biopsy-based analysis of dilated and non-dilated cardiomyopathy in the Myokard-HI-Trial

Single-AAV Base-Editing in Noonan Syndrome-associated hypertrophic cardiomyopathy

Zebrafisch-Modell für RBM20-mediierte dilatative Kardiomyopathie: Wirkung von RBM20 auf die PEVK-Domäne des Titins sowie phänotypische Untersuchung nach Morpholino-induziertem RBM20 Knock-down